A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · TroFuse-019 Phase 3Recruiting

Lead sponsor: Merck Sharp & Dohme LLC (Industry)
Enrollment: 780 (estimated)
Start date: 3 Apr 2024
Primary completion: 21 Feb 2034 (estimated)
Study completion: 23 Oct 2034
Last update posted: 15 Oct 2026

Design

Study type: Interventional
Primary purpose: Treatment
Allocation: Non randomized
Intervention model: Parallel
Masking: Single
Arms: 2

Interventions

Sacituzumab tirumotecan Biological
Pembrolizumab Biological
Cisplatin Drug
Pemetrexed Drug
Gemcitabine Drug
Carboplatin Drug
Paclitaxel Drug
Rescue medication Drug

Conditions and primary outcome

Non Small Cell Lung Cancer

Primary outcome

Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR) (Up to ~ 93 months)

Posted results on ClinicalTrials.gov

Results posted on ClinicalTrials.gov: No

Results from company and journal sources

No editor-confirmed results are on record for this study.

Publications

No PubMed citation lists NCT06312137.

CT-VCA trial quality

Loading CT-VCA scores…

Data integrity

Compare what the registry, company releases, FDA documents and publications say about this study.

Drugs on HealthTrade

Sacituzumab tirumotecan

Source

NCT06312137 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 25 Oct 2026

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.

Nothing on this page is medical or investment advice.